Magovcevic-Liebisch Ivana
SEC-identified person · CIK 1279281 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Acrivon Therapeutics, Inc. ACRV | Director | filed 2024–2026 |
| Quanterix Corp QTRX | Director | filed 2024–2026 |
| Vigil Neuroscience, Inc. VIGL | Director · President and CEO | filed 2022–2025 |
| Spyre Therapeutics, Inc. SYRE | Director | filed 2018–2023 |
| Absci Corp ABSI | Director | filed 2021–2022 |
| Applied Genetic Technologies Corp AGTC | Director | filed 2014–2021 |
| Dyax Corp DYAX | Director · GC and EVP, Administration | filed 2006–2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.